IL-13Rα2 Antibody (B-D13): sc-57267
- IL-13Rα2 Antibody (B-D13) is a mouse monoclonal IgG1, cited in 8 publications, provided at 100 µg/ml
- raised against IL-13Rα2 of human origin
- recommended for detection of IL-13Rα2 of human origin by IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IL-13Rα2 Antibody (B-D13). This work is in progress.
QUICK LINKS
SEE ALSO...
IL-13Rα2 Antibody (B-D13) is a mouse monoclonal IgG1 antibody that detects IL-13Rα2 in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). IL-13Rα2 plays a significant role in modulating interleukin-13 effects, a key cytokine involved in allergic responses and asthma. Unlike IL-13Rα1, which promotes signaling pathways leading to inflammation, IL-13Rα2 functions primarily as a decoy receptor, binding IL-13 without initiating a signaling cascade. This unique characteristic provides a mechanism for negative feedback in IL-13 signaling, helping regulate immune responses and prevent excessive inflammation. IL-13Rα2 expression is particularly prominent in glioma cells, suggesting potential roles in tumor biology and development of therapeutic strategies targeting IL-13 pathways. Anti-IL-13Rα2 antibody (B-D13) enables researchers to gain valuable insights into IL-13 signaling dynamics and implications in various diseases, including allergic conditions and cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IL-13Rα2 Antibody (B-D13) References:
- The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. | Strober, W., et al. 2009. Curr Mol Med. 9: 740-50. PMID: 19689301
- IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. | Kasaian, MT., et al. 2011. J Immunol. 187: 561-9. PMID: 21622864
- TNF-α/IL-17 synergy inhibits IL-13 bioactivity via IL-13Rα2 induction. | Badalyan, V., et al. 2014. J Allergy Clin Immunol. 134: 975-8.e5. PMID: 24954262
- IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer. | Fujisawa, T., et al. 2021. Diagnostics (Basel). 11: PMID: 34201539
- Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy. | Knudson, KM., et al. 2022. Front Immunol. 13: 878365. PMID: 35464460
- Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma. | Schmidts, A., et al. 2023. Neurooncol Adv. 5: vdac185. PMID: 36751672
- Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex. | Tollenaere, MAX., et al. 2023. JID Innov. 3: 100214. PMID: 37554517
- Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. | Brown, CE., et al. 2024. Nat Med. 30: 1001-1012. PMID: 38454126
- Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. | Brown, CE., et al. 2024. Nat Med. 30: 1501. PMID: 38514871
- IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. | Hou, AJ., et al. 2024. Neuro Oncol. 26: 1850-1866. PMID: 38982561
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-13Rα2 Antibody (B-D13) | sc-57267 | 100 µg/ml | $322.00 |